Astellas Pharma Inc. (ALPMY)
| Market Cap | 17.16B |
| Revenue (ttm) | 12.77B |
| Net Income (ttm) | 338.88M |
| Shares Out | n/a |
| EPS (ttm) | 0.19 |
| PE Ratio | 50.63 |
| Forward PE | n/a |
| Dividend | 0.51 (5.28%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 7,522 |
| Average Volume | 146,527 |
| Open | 9.25 |
| Previous Close | 9.45 |
| Day's Range | 9.25 - 9.58 |
| 52-Week Range | 8.37 - 13.14 |
| Beta | 0.12 |
| RSI | 49.33 |
| Earnings Date | Aug 1, 2025 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAG... [Read more]
Financial Performance
In 2024, Astellas Pharma's revenue was 1.91 trillion, an increase of 19.25% compared to the previous year's 1.60 trillion. Earnings were 50.75 billion, an increase of 197.72%.
Financial numbers in JPY Financial StatementsNews
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO , June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") to...
Lupin shares in focus after US Court rejects plea in Astellas Patent case
Lupin shares were in focus after a U.S. District Court rejected the proposal filed by generic drugmakers Lupin and Zydus in a legal dispute with Astellas Pharma over the interpretation of the ‘189 pat...
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging ...
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizat...
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme...
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their resea...
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY ™ (avacincaptad pegol intravitreal solution) pivotal studies TOKYO , May 1,...
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
Astellas Pharma reports FY results
Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation
Zydus Lifesciences Ltd announced that the United States District Court for the District of Delaware has ruled in favor of Astellas Pharma Inc., upholding the validity of the Japanese drugmaker’s US Pa...
Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug
Shares of Zydus Lifesciences and Lupin plunged sharply on April 16 after both companies lost a patent litigation case related to the bladder treatment drug Myrbetriq in the United States. The US Feder...
Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics presented results showing a refined approach to detect drug-induced testicular toxicity using Singlera's cell-free DNA methylation techn...
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - TOKYO , March 5, 2025 /PRNewswire/ -- Astellas ...
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug discovery...
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO , Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Ad...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
On Monday, Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (OTC: ALPMF) (OTC: ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfo...
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of l...
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Astellas Pharma Inc.
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan - ...
Astellas Pharma Non-GAAP EPS of ¥124.60, revenue of ¥1453.03B; updates FY outlook
Astellas Makes Announcement about Management Structure
TOKYO , Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective Apr...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...
Pharma Giant Warns Pills Critical For Organ Transplant Patients' to Survive May Be Completely Empty in Urgent Recall
Pharmaceutical company Astellas Pharma announced two urgent recalls for vital immunosuppressive drugs, Prograf and Astagraf XL, that are used to prevent organ rejection in transplant recipients.